Bremelanotide
Stronger clinical signalAlso known as: PT-141 · Vyleesi
A melanocortin-receptor agonist derived from Melanotan II research, FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Notable as one of the only peptides in this category with a formal drug approval.
Mechanism (plain language)
Non-selectively activates melanocortin receptors (MC3R/MC4R) in the central nervous system, acting on desire and arousal pathways rather than on genital blood flow directly, distinguishing it mechanistically from PDE5-inhibitor erectile-dysfunction drugs.
What research suggests
Two identically designed phase 3 RCTs (the RECONNECT trials) in premenopausal women with HSDD reported statistically significant increases in sexual desire and reductions in related distress versus placebo, supporting FDA approval.
Uncertainties & risks
Approved specifically for HSDD in premenopausal women, on an as-needed dosing schedule set by the label—not a general-purpose libido or performance product. Nausea, flushing, and headache are common; clinical benefit size has been debated as modest despite statistical significance.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
2019 · human
RECONNECT phase 3 trials found statistically significant increases in sexual desire and reduced related distress versus placebo.
- Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder
2020 · review
Review of phase 2/3 data supporting FDA approval, noting modest clinical benefit alongside statistical significance.